Navigation Links
Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
Date:9/11/2007

ANA598 demonstrates favorable preclinical antiviral, metabolic,

pharmacokinetic and preliminary toxicologic properties

SAN DIEGO, Sept. 11 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) presented preclinical data today on ANA598, a non-nucleoside inhibitor of the HCV NS5B polymerase, during a poster session at the 14th International Symposium on Hepatitis C Virus and Related Viruses.

The report characterized the favorable antiviral, metabolic, pharmacokinetic and preliminary toxicologic properties that supported the decision announced in June to progress ANA598 to IND enabling studies and subsequent clinical evaluation expected to commence in the first half of 2008. ANA598 is a potent, low-nanomolar inhibitor of HCV genotype 1a and 1b replicons and has exhibited good metabolic stability properties in in vitro preclinical studies. It also does not significantly inhibit or induce cytochrome enzymes, indicating that the compound has a low likelihood of producing clinical drug-drug interactions. ANA598 was well tolerated in 14-day dose range finding (DRF) animal toxicology studies at all doses tested (1 to 1000mg/kg). In in vivo preclinical studies designed to be predictive of potential human doses, trough plasma concentrations of ANA598 24 hours post dosing exceeded the EC95 for HCV genotype 1a and 1b replicon inhibition at doses corresponding to estimated human doses. The EC95 is the concentration required to suppress hepatitis C viral RNA levels by 95% in the replicon assay.

"We are pleased with the ANA598 plasma exposures we have observed in animal studies at doses that were well tolerated for 14 days," said Steve Worland, Ph.D., President and Chief Executive Of
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule, Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for Clinical Development in Chronic Hepatitis C Virus Infection
2. Anadys Reports Preclinical Data Showing ANA773 Promotes Anti-Tumor Activity of Natural Killer Cells
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... WASHINGTON , Feb. 27, 2015  Following ... Means Committee that moved H.R. 284, the Medicare ... the American Association for Homecare (AAHomecare) released a ... quick action to pass the legislation. ... in the House Ways and Means Committee is ...
(Date:2/27/2015)... 2015 Securities lawyers at Dunnam & ... Ltd. (NASDAQ: SLXP ) in connection with ... investors are encouraged to contact attorney Hamilton Lindley by ... focuses upon the shareholder value of the transaction. Under ... only $158.00 per share in cash. At least one ...
(Date:2/27/2015)... and HOUSTON, TX , Feb. 27, ... (TSX-V: EPI) and Bloom Burton & Co. Ltd. ("Bloom ... contractual lock-up (the "Lock-Up") 2,353,130 common shares of the ... originally subject to the Lock-Up. Of the Common Shares ... trading immediately upon release from the Lock-Up while the ...
Breaking Medicine Technology:Bidding Fix Takes Major Step Forward After Bipartisan Vote of House Ways and Means Committee 2ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 2ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 3ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 4
... Disease Control and Neurotoxicity Data To Be Presented ... Picoplatin as a Neuropathy-Sparing Alternative to Oxaliplatin for ... Team to Host Analyst and Investor Briefing to ... SAN FRANCISCO, Calif., May 28 Poniard Pharmaceuticals, ...
... and Melanoma Studies - Conference Call to be Hosted ... Conn., May 28 CuraGen Corporation (Nasdaq: ... data presentations from its ongoing clinical trials of CR011-vcMMAE, ... advanced breast cancer and melanoma at the 2009 Annual ...
Cached Medicine Technology:Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer 2Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer 3Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer 4Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer 5Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer 6CuraGen to Present CR011-vcMMAE Data at ASCO 2CuraGen to Present CR011-vcMMAE Data at ASCO 3CuraGen to Present CR011-vcMMAE Data at ASCO 4CuraGen to Present CR011-vcMMAE Data at ASCO 5
(Date:2/28/2015)... February 28, 2015 The MCA Youth ... Malaysia into one platform and gears towards the goal ... A series of group talks in smaller groups will ... Building, Education, Personal Development, Leadership, Entrepreneurship, Healthcare, Social and ... awareness of Malaysian youths. , Young adults ...
(Date:2/28/2015)... Gerald “Solutionman” Haman surveyed over 10,000 ... to innovative thinking. “The #1 block was lack ... tools,” reports Haman, who created the Thinkubator Innovation Studio ... felt that they did not have enough time for ... to stimulate innovation. , Solutionman’s monthly “Accelerating Innovation Training” ...
(Date:2/28/2015)... 2015 March—also known as National ... remind ourselves and others that suspected head injuries, ... Specialists (ANS). , Concussions are a form of ... of TBIs. There are 1.6-3.8 million sports-related concussions ... but it is a brain injury. Many athletes ...
(Date:2/28/2015)... A study out of the University of ... for the treatment of a hereditary ocular condition that ... by Dr. Robert MacLaren, professor of ophthalmology at the ... Journal on January 16, 2014 , the study treated ... that mostly affects men and leads to the degeneration ...
(Date:2/28/2015)... MO (PRWEB) February 28, 2015 ... provider of outsourced sales, marketing and supply chain ... client, BIOTA Botanicals, is bringing its award winning ... worldwide, BIOTA Botanicals’ products are specifically created to ... care experts, BIOTA is committed to marrying science ...
Breaking Medicine News(10 mins):Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 2Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 3Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 4Health News:New Survey Reveals “Lack of Time” Is the Number #1 Barrier to Innovative Thinking 2Health News:New Survey Reveals “Lack of Time” Is the Number #1 Barrier to Innovative Thinking 3Health News:Atlantic NeuroSurgical Specialists (ANS) Focus on National Brain Injury Awareness Month to Educate the General Public on Head Trauma 2Health News:Atlantic NeuroSurgical Specialists (ANS) Focus on National Brain Injury Awareness Month to Educate the General Public on Head Trauma 3Health News:New Gene Therapy Procedure Could Hold Key to Preventing Blindness for Certain Patients 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 3
... R.I. [Brown University] Despite evidence that feeding tubes ... for elderly patients with advanced dementia, their frequency of ... of family members finds that discussions surrounding the decision ... Advanced dementia is a terminal illness that often affects ...
... People with dementia may soon have improved oral hygiene ... four-year grant to Rita A. Jablonski, assistant professor of ... disease have all been linked to poor oral hygiene. ... for because they often are no longer able to ...
... of disease progression and response to chemotherapy in breast ... patients, but do not always agree in their predictions ... In recent years, several genomic tests have ... Dr Catherine Kelly from Mater Misericordiae University Hospital, Dublin, ...
... In a rare and medically remarkable operation, a multi-disciplinary team ... Arthur G. James Cancer Hospital and Richard J. Solove ... and pelvis of a cancer patient, and used the healthy, ... connection between his spine and remaining right pelvis to support ...
... May 4 (HealthDay News) -- U.S. health officials issued ... of liquid over-the-counter drug products that are measured and ... droppers. The U.S. Food and Drug Administration developed ... of overdoses when using liquid over-the-counter (OTC) pain relievers, ...
... , WEDNESDAY, May 4 (HealthDay News) -- A ... group of congenital heart defects that cause a major proportion ... unclear how these cardiac defects -- all malformations of the ... suggests a genetic component may play a role. "It ...
Cached Medicine News:Health News:Families need to know more about feeding tubes for elderly dementia patients 2Health News:Breast cancer multi-gene tests compared 2Health News:Breast cancer multi-gene tests compared 3Health News:Ohio State surgeons rebuild pelvis of cancer patient 2Health News:Ohio State surgeons rebuild pelvis of cancer patient 3Health News:FDA Issues Guidelines for Liquid OTC Medicines 2Health News:New Gene Linked to Congenital Heart Defects 2
... Infrapatellar Band uses an aircell ... patellar tendon helping to relieve ... patella tendonitis. Focusing the pressure ... tubercle with less constriction of ...
Both versions of the UltraSling II provide immobilization for rotator cuff repairs, capusular shifts, Bankhart repairs, glenohumeral dislocations/subluxation and soft tissue repairs/strains....
Unique V-lock strapping system prevents roll and shifting to provide secure shoulder immobilization...
... Bird and Cronin, Inc. ... of Patient Footwear, Orthopedic ... Care Products. Our products ... quality and available in ...
Medicine Products: